Press Release

RedHill Biopharma (Nasdaq: RDHL) Highlights Strategic Transformation and Expanded Commercial Growth Strategy in Virtual Investor "What This Means" Segment

Chief Business Officer, Guy Goldberg, discusses the Company's evolution into a more scalable commercial-stage business, opportunities to drive growth across its expanded GI portfolio and its long-term vision for shareholder value

--

Access the segment here

RALEIGH, N.C. and TEL-AVIV, Israel, November 17, 2026, RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that Guy Goldberg, Chief Business Officer of RedHill Biopharma, participated in a Virtual Investor "What This Means" segment.

During the interview, Mr. Goldberg discussed the strategic evolution of RedHill's business following the successful execution of two strategic transactions with mid-size pharma companies, the divestiture of Talicia and the acquisition of commercialization rights to Rebyota® and Clenpiq®, highlighting the Company's disciplined approach to capital allocation and its transition toward a broader, revenue-generating commercial specialty pharma growth business. The discussion explored the opportunities to accelerate growth across the expanded commercial GI portfolio by leveraging the Company's existing lean infrastructure, physician relationships and established market demand, as well as ongoing execution of a roll up strategy to build upon this foundation through additional complementary products. Mr. Goldberg also addressed RedHill's priorities for the coming quarters and how disciplined commercial execution, portfolio expansion and improved operating economics could support the Company's commercial growth strategy and shareholder value.

The Virtual Investor "What This Means" segment is available for on-demand viewing here.

About RedHill Biopharma

RedHill Biopharma Ltd. (Nasdaq: RDHL) is a U.S. specialty biopharmaceutical company focused primarily on the development and commercialization of proprietary drugs for gastrointestinal diseases, infectious diseases and oncology. RedHill promotes the FDA-approved gastrointestinal therapies **Rebyota®**, for the prevention of recurrent *C. diff* infection (rCDI), and the bowel preparation treatment, **Clenpiq®**. RedHill's key clinical late-stage development programs include: (i) **RHB-102 (Bekinda®)**, with a potential UK MAA for oncology support (chemotherapy and radiotherapy induced nausea and vomiting (CINV/RINV)), positive results from a U.S. Phase 3 study for acute gastroenteritis and gastritis, positive results from a U.S. Phase 2 study for IBS-D and is Phase 2-ready for GLP-1/GIP-associated GI intolerance; (ii) **opaganib (ABC294640),** a first-in-class, orally administered, sphingosine kinase-2 (SPHK2) selective inhibitor with anticancer, anti-inflammatory and antiviral activity, targeting multiple indications including; prostate cancer, with an ongoing Phase 2 study in combination with darolutamide, neuroblastoma, in collaboration with Penn State University, and for which it has FDA Orphan Drug and Rare Pediatric Disease designations with potential for a Priority Review Voucher (PRV), multiple myeloma with US National Cancer Institute (NCI) grant-funded planned Phase1b/2 clinical studies in partnership with University of Oklahoma, and virus-induced acute respiratory distress syndrome (ARDS); (iii) **RHB-204**, a next-generation optimized formulation of RHB-104, with a Phase 2-ready study for Crohn's disease (based on RHB-104's positive U.S. Phase 3 Crohn's disease study results); and (iv) **RHB-107** (**upamostat**), an oral broad-acting, host-directed, serine protease inhibitor with potential for pandemic preparedness, including COVID-19 and influenza and also targeting multiple cancer and inflammatory gastrointestinal diseases.

Visit www.redhillbio.com / X.com/RedHillBio for more information about the Company

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and may discuss investment opportunities, stock analysis, financial performance, investor relations, and market trends. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words, and include, among others, statements regarding the MAP-killing effect of RHB-204, the design, timing and conduct of any future study of RHB-204 in a MAP-positive CD patient population, the Company's diagnostic collaborations, its partnering, collaboration and grant application efforts, the scope and duration of patent coverage and regulatory designations, and RHB-204's potential as a possible therapeutic option for Crohn's disease. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: the risk that in vitro results are not predictive of results in animals or humans; the risk that the Company may not commence or complete a clinical study of RHB-204 in a MAP-positive CD patient population, or that any such study may be delayed, the risk that MAP detection diagnostics do not perform as expected

or are not available on acceptable terms, the anticipated use of NCI grant funding for the planned Phase 1b and Phase 2 trials for opaganib; planned enrollment, timing and design of the Phase 1b and Phase 2 trials and the potential benefits, if any, of opaganib in combination with CAR T-cell therapy; the risk that the NCI funding may be reduced, delayed or terminated, or may be affected by broader uncertainty regarding government funding; the risks arising with trials conducted by a third party not controlled by RedHill; the risk that the trials may be delayed or may not demonstrate safety or efficacy; the risk that the acquisition of commercialization rights for Rebyota® and Clenpiq does not result in the planned commercial growth; the risk that opaganib is not accepted into Ebola virus disease control programs, or if accepted, that it does not demonstrate efficacy; the risk that development of RHB-204 for Crohn's disease may not be completed, or if completed may not be approved or may not achieve commercial success; the risk that opaganib is not effective against the indications for which we develop our products; the risk that RHB-102 (Bekinda) does not effectively reduce GLP-1/GIP-related nausea, vomiting and diarrhea; the risk regarding the Company's ability to regain and maintain compliance with Nasdaq's listing requirements, including the minimum bid price requirement; the risk that the addition of new revenue generating products or out-licensing transactions will not occur; the risk that the Company will not receive future milestone payments under its existing agreements or that they will be less than anticipated; the risk of current uncertainty regarding U.S. government research and development funding and that the U.S. government is under no obligation to continue to support development of our products and can cease such support at any time; the risk that the FDA does not agree with the Company's proposed development plans for its programs; the risk that the Company's development programs and studies may not be successful and, even if successful, such studies and results may not be sufficient for regulatory applications, including emergency use or marketing applications, and that additional studies may be required; the risk that the Company will not successfully commercialize its products; as well as risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company's research, manufacturing, pre-clinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its commercial products and ones it may acquire or develop in the future; (ii) the Company's ability to advance its therapeutic candidates into clinical trials or to successfully complete its pre-clinical studies or clinical trials or the development of any necessary commercial companion diagnostics; (iii) the extent and number and type of additional studies that the Company may be required to conduct and the Company's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company's therapeutic candidates and commercial products; (v) the Company's ability to establish and maintain corporate collaborations; (vi) the Company's ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (vii) the interpretation of the properties and characteristics of the Company's therapeutic candidates and the results obtained with its therapeutic candidates in research, pre-clinical studies or clinical trials; (viii) the implementation of the Company's business model, strategic plans for its business and therapeutic candidates; (ix) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (x) parties from whom the Company licenses its

intellectual property defaulting in their obligations to the Company; (xi) the Company's ability to collect on its judgement against Kukbo; (xii) estimates of the Company's expenses, future revenues, capital requirements and needs for additional financing; (xiii) the effect of patients suffering adverse experiences using investigative drugs under the Company's Expanded Access Program; (xiv) competition from other companies and technologies within the Company's industry; and (xv) the hiring and employment commencement date of executive managers. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 20-F filed with the SEC on April 27, 2026. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law.

Company contact:
Adi Frish
Chief Corporate & Business Development Officer
RedHill Biopharma
adi@redhillbio.com

Investor Contact:
Jenene Thomas
JTC Team, LLC
908.824.0775
rdhl@jtcir.com

Category: Corporate